Kamada - KMDA Stock Forecast, Price & News

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Analyst Ratings Changes

KMDA has been the subject of a number of recent analyst reports. StockNews.com started coverage on shares of Kamada in a research report on Wednesday. They issued a "buy" rating for the company. TheStreet cut shares of Kamada from a "c-" rating to a "d" rating in a report on Monday, June 13th.

Kamada Price Performance

Kamada stock traded down $0.07 during trading on Wednesday, reaching $5.19. The company had a trading volume of 26,770 shares, compared to its average volume of 24,006. Kamada has a 1-year low of $4.22 and a 1-year high of $6.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.22 and a current ratio of 2.75. The firm's 50-day simple moving average is $4.78 and its 200 day simple moving average is $5.21. The firm has a market capitalization of $231.06 million, a PE ratio of -34.60 and a beta of 0.98.

Kamada (NASDAQ:KMDA - Get Rating) last issued its quarterly earnings data on Tuesday, May 17th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.07). Kamada had a negative net margin of 6.31% and a negative return on equity of 3.44%. The company had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.43 million. During the same quarter last year, the firm posted $0.06 earnings per share. As a group, equities research analysts anticipate that Kamada will post -0.07 earnings per share for the current fiscal year.